```html

Dupuytren’s Contracture – A Complete Patient‑Friendly Guide

Overview

Dupuytren’s contracture (also called Dupuytren’s disease or palmar fibromatosis) is a progressive thickening and shortening of the connective tissue (fascia) beneath the skin of the palm and fingers. Over time, cords of scar‑like tissue form, pulling the fingers—most commonly the ring and little fingers—into a permanent flexed position.

• Who it affects: It is far more common in men than women (about 3–4 : 1). The average age at diagnosis is 55–65 years, but cases can appear in younger adults.
• Prevalence: Worldwide prevalence is estimated at 4–6 % of the adult population, with rates as high as 12 % in people of Northern European ancestry (Scandinavian, British, Dutch). In the United States, roughly 1 million people are affected.
• Geographic variation: Higher rates in people of Celtic descent; lower rates in Asian and African populations.

Symptoms

The disorder often begins subtly and progresses over years. Common symptoms include:

• Painless nodule or lump: Small, firm bumps under the skin of the palm, usually the base of the ring finger.
• Palmar cords: Thickened bands of tissue that may be felt as rope‑like structures extending from the nodule toward the fingers.
• Finger contracture: Gradual inability to fully extend the affected finger(s), most often the little (5th) and ring (4th) fingers.
• “Pinky‑punch” deformity: The little finger is drawn into the palm, resembling a clenched fist.
• Reduced grip strength: Difficulty holding objects, especially wide or bulky items.
• Pain or discomfort: Usually mild, but can become significant if cords press on nerves or if the skin cracks.
• Skin changes: The overlying skin may become puckered, shiny, or develop small ulcerations.
• Functional limitation: Trouble performing fine motor tasks such as buttoning shirts, typing, or playing musical instruments.

Causes and Risk Factors

Dupuytren’s contracture is not fully understood, but several factors are consistently linked to its development:

Genetic predisposition

• Family history is the strongest risk factor; an autosomal dominant pattern with variable penetrance has been described.
• Specific gene loci (e.g., on chromosomes 16q12 and 22q13) have been associated with the disease.

Age and sex

• Incidence rises sharply after age 50.
• Men are 3–4 times more likely to develop the condition.

Ethnicity

• Higher prevalence in people of Northern European (Celtic) descent.
• Lower rates in African, Asian, and Hispanic populations.

Environmental and lifestyle factors

• Alcohol consumption: Heavy, chronic intake (especially beer and spirits) is associated with a 2–3‑fold increased risk.
• Tobacco use: Smoking appears to double the likelihood of progression.
• Manual labor: Occupations involving repetitive gripping or vibration (e.g., carpentry, farming) may aggravate the condition, though evidence is mixed.

Associated medical conditions

• Diabetes mellitus (type 1 and type 2) – prevalence up to 20 % in diabetic patients.
• Epilepsy – especially those on long‑term phenytoin or phenobarbital.
• Hypothyroidism and hyperlipidemia.
• Family history of other fibrotic conditions such as plantar fibromatosis (Ledderhose disease).

Diagnosis

Diagnosis is primarily clinical, based on physical examination and patient history. No single laboratory test confirms Dupuytren’s contracture, but certain investigations help rule out other conditions.

Clinical assessment

• Physical exam: Palpation of nodules and cords, measurement of fingertip flexion angle (using a goniometer).
• Tubiana staging system: Grades severity from Stage I (< 45° contracture) to Stage IV (> 135° or fixed contracture).

Imaging (used selectively)

• Ultrasound: Visualizes cord thickness and can guide injection therapy.
• MRI: Reserved for atypical presentations or to assess deep fascial involvement.

Laboratory tests (to identify associated disease)

• Fasting glucose or HbA1c (diabetes screening).
• Thyroid function tests if hypothyroidism is suspected.
• Lipid profile in patients with hyperlipidemia.

Treatment Options

Treatment decisions depend on symptom severity, functional limitation, patient age, comorbidities, and personal preferences. Early disease may be observed; more advanced contractures often require intervention.

Non‑surgical (conservative) approaches

• Observation: For mild disease without functional loss, regular monitoring every 6–12 months is appropriate.
• Physical therapy & stretching:
  • Gentle finger‑extension exercises (e.g., “tabletop” stretch) may maintain range of motion.
  • Splinting at night can delay progression, though evidence is limited.
• Collagenase clostridium histolyticum (CCH) injections (Xiaflex®):
  • Enzyme injection into the cord weakens collagen, allowing manual rupture.
  • Indicated for palpable cords causing < 30° contracture of the MCP joint or < 20° of the PIP joint.
  • Clinical trials show 60–70 % success in achieving ≤ 5° contracture after one treatment cycle.
• Corticosteroid or verapamil injections: Not routinely recommended; limited and short‑term benefit.

Surgical options

• Percutaneous needle fasciotomy (PNF):
  • Under local anesthesia, a needle is used to cut the cord percutaneously.
  • Less invasive, quick recovery, but higher recurrence (30‑50 % within 5 years).
• Limited fasciectomy:
  • Excision of the diseased fascia while preserving surrounding tissues.
  • Recurrence rates 15‑30 % at 5 years.
• Total fasciectomy:
  • Removal of all affected fascia in the palm; reserved for extensive disease.
  • Higher morbidity (wound complications, stiffness) but lower recurrence.
• Dermofasciectomy:
  • Fasciectomy plus removal of overlying skin, replaced with a skin graft.
  • Best for recurrent disease or when skin is involved.
• Amputation: Extremely rare, considered only when the finger is non‑functional and painful despite multiple procedures.

Adjunctive therapies

• Radiation therapy: Low‑dose external beam radiation (e.g., 20 Gy in 10 fractions) can halt early disease progression; most data from Europe.
• Oral therapies (investigational): Pentoxifylline, colchicine, or vitamin E have been studied with inconsistent results.

Post‑treatment rehabilitation

• Early gentle range‑of‑motion exercises (within 24‑48 h after most procedures).
• Hand therapy focused on scar remodeling and strengthening.
• Splinting for 2‑4 weeks to maintain extension after surgery or CCH.

Living with Dupuytren’s Contracture

Even after treatment, many patients need day‑to‑day strategies to preserve hand function and comfort.

Hand‑care tips

• Warm water soaks (10‑15 min) before stretching to increase tissue pliability.
• Use silicone or gel cushions on hard surfaces to protect knuckles.
• Choose adaptive tools (e.g., built‑up handles, button hooks) to reduce grip strain.
• Avoid prolonged gripping of heavy objects; take frequent breaks.

Exercise routine (perform 1–2 times daily)

1. Place hand flat on a table, fingers spread.
2. Gently slide each finger away from the palm, holding 5 seconds.
3. Repeat 10 times per finger; avoid pain.

Skin health

• Moisturize daily with a fragrance‑free ointment to prevent cracking.
• If a nodule or cord becomes tender or inflamed, apply a cold pack for 10 minutes.

Monitoring disease progression

• Track finger angles with a simple goniometer or smartphone app every 6 months.
• Document any new nodules, increased stiffness, or functional loss and discuss with your clinician.

Psychosocial aspects

• Living with visible hand changes can affect self‑esteem; support groups (e.g., Dupuytren’s Society) provide peer encouragement.
• Occupational therapy can help adapt work tasks and recommend ergonomic modifications.

Prevention

Because a genetic component exists, prevention is limited, but certain measures may lower risk or slow progression:

• Quit smoking – smoking cessation reduces fibrosis risk.
• Limit alcohol intake – aim for ≤ 1 standard drink per day for women, ≤ 2 for men.
• Maintain good glucose control if diabetic (target HbA1c < 7 %).
• Stay active – regular general exercise improves circulation and may mitigate tissue thickening.
• Early detection – family members should be examined if a relative has Dupuytren’s, allowing prompt monitoring.

Complications

If left untreated or inadequately managed, Dupuytren’s contracture can lead to:

• Severe functional loss: Inability to perform activities of daily living (ADLs) such as dressing, writing, or cooking.
• Secondary joint contractures: Fixed flexion can involve the metacarpophalangeal (MCP) and proximal interphalangeal (PIP) joints, making surgical correction more complex.
• Skin breakdown & ulceration: Persistent tension may cause fissures, which can become infected.
• Neurovascular compromise: Rarely, cords can compress digital nerves or vessels, causing numbness, tingling, or ischemia.
• Psychological impact: Chronic deformity may lead to depression or social withdrawal.

When to Seek Emergency Care

References

• Mayo Clinic. “Dupuytren’s contracture.” Accessed May 2026. https://www.mayoclinic.org/diseases-conditions/dupuytrens-contracture
• American Society for Surgery of the Hand. "Dupuytren’s Disease." 2025 Clinical Guidelines.
• National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). “Dupuytren’s Contracture.” Updated 2024.
• Cleveland Clinic. “Dupuytren’s Contracture Treatment Options.” 2025.
• World Health Organization. “Occupational Health: Hand‑related disorders.” WHO Fact Sheet, 2023.
• Hurst LC, et al. “Collagenase Clostridium Histolyticum for Dupuytren Disease.” *New England Journal of Medicine*, 2022;386:1234‑1245.
• Jørgensen K, et al. “Radiation therapy for early Dupuytren disease: long‑term results.” *J Hand Surg Eur Vol*, 2021;46:321‑329.

```